Personalized nursing service @ home

Nex2You

Stiv@Home

For more information please send mail to info@bayer.be

* Nex2You: for patients receiving Sorafenib.
  Stiv@Home: for patients receiving Regorafenib.
Dear Colleagues,

It is our pleasure to welcome you to the XXXth Edition of the Belgian Week of GastroEnterology. Enclosed you will find the complete program of this meeting. Many high quality abstracts, illustrating the high level of both basic and clinical research in Belgium, have been selected for oral presentation during the scientific meeting.

Besides these scientific sections that constitute the backbone of the congress for many years, the BWGE 2018 offers several other attractive sessions and activities!

The program has been substantially changed compared to previous editions, as we start already on Wednesday afternoon with several exciting sessions, relevant for both clinicians and scientists. This is also the aim of the whole Belgian Week: bringing together clinicians and researchers in a stimulating meeting.

The scientific steering committee decided not to organise a Plenary Session of the Belgian Week of GastroEnterology, so the best abstracts of the several societies and research groups remain an integral part of the dedicated sessions. Several state-of-the-art lectures by national and international key-opinion leaders figure throughout the program and numerous satellites, organized by some of our sponsors, further add to the number of interesting lectures to attend.

Posters will be permanently displayed on interactive screens in the exhibition hall. Some of the best posters will be discussed during lunchtime in a separate area in the exhibition hall. We encourage you to attend these sessions and support our young researchers.

The ultrasound course (with a first session on Wednesday and a second session on Thursday) is intended for both unexperienced and experienced sonographers, with possibility to train on healthy volunteers as well as on sophisticated phantoms mimicking human disease and real time imaging.

The Belgian Society of Gastrointestinal Endoscopy organises for the second time a live endoscopy session, scheduled on Friday afternoon.

The Young Belgian Association for the Study of the Liver again participates with an ethics and economy-accreditated scientific session on Wednesday.

During the Interactive Case Report Session on Wednesday afternoon and on Thursday morning, interesting and rare cases will be discussed and commented on.

Brand new this year is the session on Proctology on Friday morning!

On Wednesday evening, after the scientific sessions, we welcome you at our get-together reception in the exhibition hall, an excellent occasion to meet friends and colleagues! Do not forget to join as for the celebration of this XXXth edition on Thursday evening at the MAS, Museum on the roof top, with a splendid view of the harbor and the city.

We hope you will enjoy a stimulating scientific meeting!
## Index

| Welcome | 3 |
| General Information | 6 |
| Steering Committee | 7 |
| Invited Lectures | 8 – 9 |
| Satellite Symposia | 10 – 11 |

### Wednesday February 21

- Belgian Inflammatory Bowel Diseases Research and Development (BIRD) | 13 – 14
- E-Posters BIRD | 16 – 19
- E-Posters Helicobacter | 19
- Young BASL | 20
- Belgian Pancreatic Club (BPC) | 22
- Case Reports Session 1 | 23
- Ultrasound Course Session 1 | 24
- Welcome Reception | 25

### Thursday February 22

- Belgian Association for the Study of the Liver (BASL) | 27 – 33
- Congress Overview | 34 – 35
- Belgian Association for the Study of the Liver (BASL) | 36 – 37
- E-Posters BASL | 38 – 39
- Belgian Network on Gastrointestinal Regulatory Mechanisms (GIREM) | 40 – 43
- Case Reports Session 2 | 44
- E-Posters with Short Talk: Basic | 45
- Belgian Inflammatory Bowel Diseases Research and Development (BIRD) | 46 – 48
Thursday February 22

E-Posters Belgian Society of Gastrointestinal Endoscopy (BSGIE) 49
Belgian Society of Gastrointestinal Endoscopy (BSGIE) 50 – 52
Ultrasound Course Session 2 53
XXXth Anniversary Dinner & Party 54

Friday February 23

BSGIE Live Transmission Session 55
BWGE 2018 Awards Ceremony 56
Belgian Group of Proctology 57
Belgian Group for Digestive Oncology (BGDO) 58 – 62
E-Posters Belgian Group for Digestive Oncology (BGDO) 62 – 63
Working Group of Digestive Pathology 64 – 65
Belgian Society for Paediatric Gastroenterology, Hepatology and Nutrition (BeSPGHAN) 66 – 67
E-Posters BeSPGHAN 67
E-Posters with Short Talk: Clinical 68 – 69
BWGE 2019 Save the Date 70
BINASTORIA Meeting 71
CME credits will be provided by online submission to the registered delegates who have attended the sessions. The file from the online accreditation registrations will be sent to the INAMI/RIZIV end of March 2018.

Dutch, French and English. English for abstracts, slides and announcements. As proposed at the Steering Committee of 1995, Belgian authors may present their original papers in their mother tongue.

BWGE XXXTH ANNIVERSARY EVENT AND DINNER
MAS Museum, Antwerpen
Thursday February 22th, 2018

VENUE
HILTON ANTWERPEN
Groenplaats, 32 - 2000 Antwerpen
Tel: +32 3 204 12 12
Website: www.hilton.com/hotel/antwerp

EVENT COORDINATOR / SCIENTIFIC SECRETARY
DME-EVENTS SPRL / BVBA - ANNE-FRANCE DE MEYER
57 av. G. Demeylaan - 1160 Bruxelles / Brussel
Tel. +32 477.27.00.45
E-mail: anne.france.de.meyer@dme-events.eu
STEERING COMMITTEE

SCIENTIFIC COORDINATORS

SVEN FRANCUQUE | ISABELLE COLLE

SEVEN SOCIETIES

PHILIP CAENEPEEL, MARC PEETERS
VVGE: Vlaamse Vereniging voor GastroEnterologie.

CATHERINE VAN KEMSEKE, GONTRAN VERSET
SRBGE: Société Royale Belge de GastroEnterologie.

DANIEL BLERO, DANNY DE LOOZE, HUBERT PIESSEVAUX
BSGIE: Belgian Society of Gastrointestinal Endoscopy.

ARNAUD DE ROOVER, JAN LERUT
RBSS: Royal Belgian Society of Surgery.

LIEVEN VAN HOE, CRISTINA DRAGEAN
BSR: Belgian Society of Radiology, Section of Abdominal Imaging.

CHRISTOPHE MORENO, ANJA GEERTS
BASL: Belgian Association for the Study of the Liver.

IVAN BORBATH, MARC PEETERS
BGDO: Belgian Group of Digestive Oncology.

RESEARCH GROUP

INGE DEPOORTERE
GIREM: Belgian Network on Gastrointestinal Regulatory Mechanisms.

ANNE HOORENS, ANN DRIESEN
WGDP: Working Group of Digestive Pathology.

ILSE HOFFMAN, FRANÇOISE SMETS
BESPghan: Belgian Society for Paediatric Gastroenterology Hepatology and Nutrition.

ANDRÉ VAN GOSSUM
SBNC: Société Belge de Nutrition Clinique.

DIRK YSEBAERT
VVKVM: Vlaamse Vereniging voor Klinische Voeding en Metabolism.

JEAN-FRANÇOIS RAHIER
PIETER HINDRYCKX
BIRD: Belgian IBD Research and Development.

MYRIAM DELHAYE
BPC: Belgian Pancreatic Club.

PATRICK BONTEMPS, FAZIA MANA
BHPST: Belgian Microbiota and Helicobacter Study Group.

OLIVIER DETRY, JACQUES PIRENNE
BLIC: Belgian Liver Intestine Committee.

ROLAND HUSTINX, CHRISTOPHE DEROOSE
BELNUC: Belgian Society of Nuclear Medicine.

LEO VAN GRUNSVEN
Basic research groups.

YVES-PAUL VANDEWYNCKEL
Young BASL.

ANNELEEN VAN HOOTEGEM
Young VVGE.

JEFFREY SCHOUTEN
Ultrasound Course.
Wednesday February 21

**BIRD**
- Massimo Fantini / Rome, Italy: Why animal models of IBD are still relevant.
- Wiebe Vanhove / Leuven: Benefits and limitations of pre-clinical in vitro and ex vivo work.
- Gerhard Rogler / Zurich, Switzerland: The exposome in IBD: what needs to be done?

**BPC**
- M. Delhaye, P. Demetter / ULB Erasme: Diagnosis of pancreatic cystic lesions.

**Young BASL**
- Renee Tolba / Aachen, Germany: Animal models in liver disease: from law to practice.
- Johan Neyts / KULeuven: Antiviral therapy: From bench to bedside.

Thursday February 22

**BASL**
- Vincent Leroy / Grenoble, France: Diagnostic approach of cholestasis: when it is neither PBC nor PSC.
- Valerio Lucidi / ULB, Brussels: Surgical management of early HCC: Resection is the first option.
- Jacques Pirenne / KULeuven: Surgical management of early HCC: Liver transplantation is the first option.

**GIREM**
- G. MAZZUOLI-WEBER / Hannover, Germany: Enteric neurons and mechanosensitivity: MEN at work.
- J. FICHNA / Lodz, Poland: Lipids and irritable bowel syndrome – an (un)likely connection.

**BIRD**
- Charlie Lees / Edinburgh, UK: JAK inhibitors: can they replace biologicals?
- Marc Van Ranst / Leuven: JAK inhibitors: is the increased risk of viral infections a real threat?
- Shomron Ben-Horin / Tel Aviv, Israel: Initiating biological therapies in IBD: Do I have to use other drugs for CD than for UC?

**BSGIE**
- Marek Bugajski / Warshaw, Poland: ESGE quality indicators for lower GI endoscopy.
- E. Dekker / Amsterdam, The Netherlands: Optical diagnosis: How do I do it?
Friday February 23

**BGDO**

- Magali Svrcek / Paris, France: MSI testing in GI cancer: challenges and pitfalls.
- Marc Van Den Eynde / UCL Bruxelles: Highlights of the year: Upper GI cancers
- Anne Demols / ULB Bruxelles: Highlights of the year: Hepato-Bilio-Pancreatic cancers
- Hans Prenen / UZ Leuven: Highlights of the year: Colo-Rectal cancers

**DIGESTIVE PATHOLOGY**

- M. Rugge / Padova, Italy: Non-HP gastritis.
- G. Cathomas / Liestal, Switzerland: Non-IBD colitis.
- L. Libbrecht / UCL Saint-Luc: Disorders of the colon secondary to diagnostic procedures and treatments unrelated to drugs.

**PROCTOLOGY**

- D. DE LOOZE / UZ Gent: Sexually transmitted diseases of the anorectum.
- O. RICHEL / Amsterdam, Netherlands: Manifestations of Human Papilloma Virus infection at the anal canal – anal intraepithelial neoplasia – early detection and prevention.

**BESPGHAN**

- Els Van de Vijver / UZ Antwerpen: Diagnostic value of faecal calprotectine.
- Isabelle Scheers / UCL St Luc: Diagnostic and therapeutic challenges in pediatric chronic Pancreatitis.
**Wednesday 21**

**Targeting IL-23/-12 in Crohn’s disease: Experience from across the border.**
Prof. T. KUHBACHER, Hamburg (Germany)

---

**Thursday 22**

**Changing perspectives in primary biliary cholangitis (PBC)**
Prof. F. NEVENS, UZ Leuven
Prof. C. MORENO, ULB Erasme Brussels

**Screening and awareness initiatives in Belgium**
Prof. I. COLLE, ASZ Aalst
Dr. B. BASTENS, CHC Liège
Prof. J. SCHOUTEN, AZ Nikolaas
Dr. C. VANSTEENKISTE, AZ Maria Middelares Gent

**PK/PD for guiding therapy with vedolizumab: Lessons from clinical experience**
Prof. S. BEN-HORIN, Tel-Aviv (Israel)

**Beyond the efficacy of HCV treatments: What does really matter? A pros and cons debate**
Dr. N. REAU, Chicago (USA)
Dr. A. BROWN, London (UK)

**Is Nash the next HCV?**
Prof. P. MATHURIN, Lille (France)

**Anticoagulation & GE: Where are we after 5 years of NOAC?**
Prof. P. DEPREZ, UCL Saint-Luc Brussels,
Prof. K. JOCHMANS, UZ Brussels
Wednesday 21
New MOAs /pathways in the IBD World
Pfizer Symposium
Prof. Charlie Lees (UK)

Optimizing sequential treatment in gastric cancer
Prof. M. VAN DEN EYNDE, UCL Saint-Luc Brussels
Prof. E. VAN CUTSEM, UZ Leuven
Prof. J-L. VAN LAETHEM, ULB Erasme, Brussels
Prof. M. PEETERS, UZAntwerpen

Redefining third line therapy in metastatic colorectal cancer
Prof. M. VAN DEN EYNDE, UCL Saint-Luc Brussels
Prof. E. VAN CUTSEM, UZ Leuven
Prof. J-L. VAN LAETHEM, ULB Erasme, Brussels
Prof. M. PEETERS, UZAntwerpen

Are we understanding immunotherapy ?
Prof. P. COULIE, UCL Saint-Luc Brussels
Prof. E. VAN CUTSEM, UZ Leuven

Friday 23

Optimizing sequential treatment in gastric cancer
Prof. M. VAN DEN EYNDE, UCL Saint-Luc Brussels
Prof. E. VAN CUTSEM, UZ Leuven
Prof. J-L. VAN LAETHEM, ULB Erasme, Brussels
Prof. M. PEETERS, UZAntwerpen

Redefining third line therapy in metastatic colorectal cancer
Prof. M. VAN DEN EYNDE, UCL Saint-Luc Brussels
Prof. E. VAN CUTSEM, UZ Leuven
Prof. J-L. VAN LAETHEM, ULB Erasme, Brussels
Prof. M. PEETERS, UZAntwerpen

Are we understanding immunotherapy ?
Prof. P. COULIE, UCL Saint-Luc Brussels
Prof. E. VAN CUTSEM, UZ Leuven
Targeting IL-23/-12 in Crohn’s disease: experience from across the border

Wednesday 21 February 2018
13h15 - 14h00

Speaker
Prof. Dr. med. habil. Tanja Kühbacher
Head of the Department of Gastroenterology / Internal Medicine,
Asklepios Westklinikum Rissen, Hamburg

Moderator
Prof. Dr. Séverine Vermeire,
UZ Leuven

Venue
Hilton Hotel Antwerp
Conference Center, Room “Lijn”
**SESSION 1: From the bed back to the bench**  
**CHAIRS:** Pieter Hindryckx (Gent), Gianluca Matteoli (Leuven)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:15</td>
<td><strong>Satellite Symposium: Janssen-Cilag.</strong></td>
<td>Invited speaker: Tanja KÜHBACHER / Hamburg, Germany</td>
</tr>
<tr>
<td>14:00</td>
<td><strong>Invited Lecture: Why animal models of IBD are still relevant.</strong></td>
<td>Massimo Fantini / Rome, Italy</td>
</tr>
<tr>
<td>14:25</td>
<td><strong>I01 Aberrant Muc1 and Muc13 expression in association with Par polarity complex and Vip dysfunction in a colitis T cell transfer model.</strong></td>
<td>T. BREUGELMANS, H. VAN SPAENDONK, M. HEYLEN, J. DE MAN, B. DE WINTER, A. SMET / UAntwerpen</td>
</tr>
<tr>
<td>14:45</td>
<td><strong>I03 Baseline ILC1 distribution in blood predicts response to ustekinumab in patients with refractory Crohn’s disease.</strong></td>
<td>B. CREYNS, B. VERSTOCKT, J. CREMER, M. FERRANTE, S. VERMEIRE, J. CEUPPENS, G. VAN ASSCHE, C. BREYNAERT / KULeuven</td>
</tr>
<tr>
<td>15:05</td>
<td><strong>Invited Lecture: Benefits and limitations of pre-clinical in vitro and ex vivo work.</strong></td>
<td>Wiebe Vanhove / Leuven</td>
</tr>
<tr>
<td>15:30</td>
<td><strong>Coffee Break</strong></td>
<td></td>
</tr>
</tbody>
</table>
SESSION 2: The forgotten environment in IBD
CHAIRS: Edouard Louis (Liège), Anneline Cremer (Brussels)

16:00 105 Serum proteomic analysis characterizes newly diagnosed Crohn’s disease and ulcerative colitis depending on the age at diagnosis.

16:10 106 Serum proteomic profiling reveals changes in inflammatory profiles with consecutive biological therapies in patients with inflammatory bowel disease.

16:20 107 Protein biomarkers identify subclinical inflammation patterns in first degree relatives of patients with inflammatory bowel disease.

16:30 108 Decreased leukocyte trafficking may contribute to vedolizumab refractory disease after anti-TNF exposure in patients with ulcerative colitis.
B. VERSTOCKT, S. VERSTOCKT, M. DE BRUYN, K. MACHIELS, H. BLEVI, V. BALLET, G. VAN ASSCHE, S. VERMEIRE, M. FERRANTE / UZ Leuven

16:40 Invited Lecture: The exposome in IBD: what needs to be done?
Gerhard Rogler / Zurich, Switzerland.

17:00 Satellite symposium Pfizer
Invited speaker: Charlie Lees / UK

17:45 BIRD General Assembly
New MOAs/pathways in the IBD world

Satellite Symposium

Wednesday February 21, 2018
Timing: 17:00 – 17:45

30th BWGE -2018
Hilton Hotel Antwerp
Room Lijn

Speaker
Prof. Charlie Lees

- Gastroenterologist Western General Hospital, Edinburgh & senior lecturer at the University of Edinburgh
- Chair educational committee of the European Crohn’s & Colitis Organisation
- Chair of the Scottish Society of Gastroenterology IBD Interest Group
I17  **Immunosuppressive co-treatment with Infliximab and Adalimumab is not superior to anti-TNF monotherapy to prevent treatment failure and treatment discontinuation in ulcerative colitis.**
S. VIEUJEAN, E. LOUIS, C. REENAERS / CHU Sart Tilman, Liège

I18  **Dried Blood Spot Sampling Can Facilitate Therapeutic Drug Monitoring of Vedolizumab Therapy.**

I19  **Adaptive dosing during infliximab induction therapy can improve mucosal healing rates in patients with ulcerative colitis.**

I20  **Reactive dose escalation of infliximab in patients with Crohn’s disease in TAILORIX leads to improved outcomes.**

I21  **Infliximab exposure predicts superior endoscopic outcomes in patients with active Crohn’s disease: Pharmacokinetic-pharmacodynamic analysis of TAILORIX.**

I22  **Potential diagnostic biomarkers of Ulcerative colitis-associated colorectal dysplasia.**
I23 Golimumab Dried Blood Spot Analysis (GOUDA): A Prospective Trial to Validate Golimumab Concentration Analysis Using the Dried Blood Spot Methodology.


I24 Infliximab and Vedolizumab Show a Different Effect on Clot Formation in Inflammatory Bowel Disease Patients.


I25 Epidemiology of Clostridium difficile infections in IBD over two decades.


I26 Proteomic analysis highlights divergences and convergences between ileal and colonic pathological processes involved in Crohn’s ulcers.


I27 Serum proteomic profiling in Crohn’s disease patients undergoing ileocolonic resection reveals discriminative inflammatory markers for endoscopic recurrence.


I28 Quantitative microbiome profiling changes the described dysbiotic state in inflammatory bowel disease.

I29  Illegal gene expression changes are associated with colonic disease activity in patients with ulcerative colitis.
M. VANCAMELBEKE, S. VERSTOCKT, M. FERRANTE, G. VAN ASSCHE, S. VERMEIRE, I. CLEYNEN / KULeuven

I30  Low adalimumab serum levels at week 4 provoke immunogenicity and influence therapy outcome in anti-TNF naive Crohn’s disease patients.

I31  Filgotinib (GLPG0634, GS-6034), a JAK-1 Selective Inhibitor, Significantly Reduces Gut Tissue pSTAT3 in Crohn’s Disease Patients.

I32  Effect of disease duration and location on clinical remission in Crohn’s disease patients treated with filgotinib, a selective JAK1 inhibitor: post-hoc analysis from the Phase 2 FITZROY study.

I33  Serum markers predict outcome to ustekinumab in patients with refractory Crohn’s disease and provide insides in the mechanism of action.

I34  The interaction between intestinal permeability disturbances and inflammation in a chronic colitis mouse model, studied over time.

I35  Beclomethasone dipropionate is effective for microscopic colitis: results of an open label multicenter study (COLCO).

I37  A prospective trial to evaluate the feasibility of a mobile app in patients with inflammatory bowel disease under maintenance therapy.

I38  Right colectomy and ileocaecal resections for colorectal cancer and Crohn’s disease: assessment of postoperative results over a 5-year period.
SESSION 1: Exchanging experiences in basic and clinical research in hepatology: from ethics and methodology to results and clinical applicability

CHAIRS: Inge Mannaerts (UZ Brussel), Rob Bielen (Hasselt University)

14:00 BASL best clinical paper MSD 2017 “Intensive Enteral Nutrition Is Ineffective for Patients With Severe Alcoholic Hepatitis Treated With Corticosteroids.”
Christophe Moreno /ULB Erasme Brussels

14:20 BASL best basic paper MSD 2017 “A Glycomics-Based Test Predicts the Development of Hepatocellular Carcinoma in Cirrhosis.”
Xavier Verhelst /UZ Gent

14:40 Invited Lecture: Animal models in liver disease: from law to practice.
Renee Tolba /Aachen, Germany

15:25 Coffee break

15:45 Starter’s talk: “Systems Serology Analysis of Human Alcoholic Liver Diseases”.
Antonella Putignano /ULB Erasme Brussels

15:55 Starter’s talk: “The role of the intrahepatic vascular resistance and its underlying mechanisms in the pathophysiology of NAFLD”.
Denise van der Graaff /UAntwerpen

16:05 Invited Lecture: “Antiviral therapy: from bench to bedside.”
Johan Neyts /Rega Institute, Leuven

16:50 Closing remarks
Need to explain the exocrine pancreatic insufficiency to your patients?

A guide exists with informations & animations to support you and help them for a better understanding!

www.e-guide-visuel-insuffisance-pancreatique-exocrine.be
www.visuele-e-gids-exocriene-pancreasinsufficientie.be
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>Invited</td>
<td>Diagnosis of pancreatic cystic lesions. The view of the clinician – The view of the pathologist.</td>
<td>M. Delhaye, P. Demetter / ULB Erasme, Brussels</td>
</tr>
<tr>
<td>14:45</td>
<td>P 02</td>
<td>Long term outcome of patients with pancreatic duct disruption.</td>
<td>M. Arvanitakis, A. Bourguignon, M. Delhaye, J. Devière, C. Matos / ULB Erasme Brussels, Champalimaud Clinical Center, Lisbon, Portugal</td>
</tr>
<tr>
<td>15:00</td>
<td>P 03</td>
<td>Improvement of pancreatic endocrine function after endoscopic treatment of chronic pancreatitis.</td>
<td>S. Kautbally, M. Hermans, T. Moreels, T. Aouattah, E. Perez-Cuadrado-Robles, P. Deprez /UCL Saint-Luc Brussels</td>
</tr>
<tr>
<td>15:15</td>
<td>Invited</td>
<td>Management of autoimmune pancreatitis in 2018.</td>
<td>J. van Hooft /Amsterdam, Netherlands</td>
</tr>
<tr>
<td>15:45</td>
<td></td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>16:10</td>
<td>P 04</td>
<td>Severe panniculitis and polyarthritis.</td>
<td>A. Raptis, M. Plier, N. Jabbour, P. Durez, M. Komuta / UCL Saint-Luc Brussels</td>
</tr>
<tr>
<td>16:30</td>
<td>P 06</td>
<td>A rare cause of repetitive acute pancreatitis.</td>
<td>A. Dupin, J. Loly, P. Gast, T. Mesureur, E. Louis / CHU Sart Tilman, Liège</td>
</tr>
<tr>
<td>16:40</td>
<td>P 07</td>
<td>EUS guided pancreaticogastrostomy.</td>
<td>C. Amicone, P. Gast, JP Loly, E. Louis / CHU Sart Tilman, Liège</td>
</tr>
<tr>
<td>16:50</td>
<td>P 08</td>
<td>A rare but morphological characteristic cystic lesion of the pancreas.</td>
<td>A. Hoorens, L. Ferdinande, F. Berrevoet, P. Smeets / UZ Gent</td>
</tr>
</tbody>
</table>
An unusual cause of bleeding in a cirrhotic patient.


A case of acute hepatitis under Nivolumab treatment.

L. WUYTS, A. JANSSENS, L. VONGHIA, P. MICHEISEN, J. VAN MEERBEEK, S. FRANCQUE, T. VANWOLLEGHEM / UZAntwerpen

Endoscopic submucosal dissection of a suspicious esophageal lesion


Terminal ileitis after kidney transplantation: Crohn’s disease or other cause?

E. MOTTÉ, L. PIPELEERS, J. SENNESAEI, D. URBAIN, F. MANA / UZ Brussel

Uncommon cause of cholangiopathy in a cirrhotic patient: EUS finding


Infectious complications in a patient with automated low-flow ascites pump: a unique case report


Acute esophageal mucosal damage after Lugol staining


A case of portal vein aneurysm

This year, the Belgian week organizes once again a practical, hands-on sessions in ultrasound on Wednesday and Thursday afternoon.

Wednesday afternoon the course will focus on normal anatomy and abdominal pathology for trainees in ultrasound. Participants will be divided according to the level of experience: Normal anatomy will be demonstrated on healthy volunteers for absolute beginners. Experienced participants will be demonstrated abdominal pathology on simulators.

This course offers the possibility to get acquainted with ultrasound recordings of rare (and not so rare) gastro-intestinal disorders, to improve and upgrade your ultrasound skills. Depending on the interests of the participants, we will focus on liver tumors, vascular liver diseases, liver cirrhosis and its complications, inflammatory bowel disorders, general bowel disorders…

This course has been organized successfully during numerous international meetings (e.g. EASL).
Welcome Drink

WEDNESDAY 21 FEBRUARY

17h00 - 18h30

IN THE EXHIBITION AREA
The recent update to the EASL clinical practice guidelines for the diagnosis and management of patients with PBC is contributing to a change in perception of the disease and in understanding of how patients with PBC should be managed.

This educational symposium will explore the epidemiology, patient treatment and the emerging therapeutic options and the clinical impact of the new guidelines. We hope you will be able to join us for an interactive and engaging discussion about this evolving therapy area.

Breakfast will be provided.
08:00 Breakfast Satellite Symposium INTERCEPT
Invited Speakers: Prof. F. NEVENS, (UZ Leuven) / Prof. C. MORENO, (ULB Erasme Brussels)

SESSION 1
CHAIRS: Anja Geerts (UZGent), Jean Delwaide (ULiège)

08:30 A 01 Screening for Hepatitis C at the emergency department: baby boomers should also be screened in Belgium.

08:40 A 02 The thrombogenic risk induced by intraportal infusion of Adult Derived Human Liver Stem/Mesenchymal Cells in Wistar rats can be controlled with a combination of anticoagulant drugs, heparin and bivalirudin.

08:50 A 03 Liver stiffness and steatosis evaluation by transient elastography in obese patients: baseline results analysis from a prospective Belgian study.
N. LANTHIER, S. HIEL, J. RODRIGUEZ, B. DELIRE, M. DE BARCY, J. THISSEN, N. ELZENNE / UCL Saint-Luc Brussels

09:00 A 04 Small for Size Syndrome and Hypoxia: lessons learned from the associated liver partition and portal vein ligation for staged hepatectomy (ALPPS procedure in rats).

09:10 A 05 A new “treatment-response score” for auto immune hepatitis is predictive of long-term event-free survival and overall survival. A multicenter Belgian cohort study.

09:20 A 06 Generation of a unique liver progenitor cell gene signature to identify LPCs and LPC activation in chronic liver diseases.
The outcome of acute-on-chronic liver failure in the intensive care is similar to a propensity matched ICU population without liver disease.


Transcriptional repressors Zeb1 and Zeb2 regulate collagen production in drug-induced hepatic stellate cell activation in mice.

I. MANNAERTS, L. STRADIOT, N. EYSACKERS, L. VAN GRUNSVEN / VUB, Jette

Individualized prediction of the risk of liver-related death in patients with alcoholic cirrhosis.


Is it too early to expand beyond the Milan Criteria for liver transplantation? A retrospective, multicentric study in Belgium.


Transcriptomic profiling of intrahepatic B cells suggests a B-cell impairment in the Immune Active phase of Chronic Hepatitis B.

Abbvie has the great pleasure to invite you to our symposium during the XXVIIIth edition of the Belgian Week of Gastroenterology

Towards the eradication of HCV

Thursday February 22, 2018 At 12h00

Moderators

- Prof. Christophe Moreno
  Erasme Hospital & president of BASL
- Prof. Wim Laleman
  UZ Leuven

Screening and awareness initiatives in Belgium

- Prof. Isabelle Colle, ASZ Aalst
- Dr. Boris Bastens, CHC Liège
- Prof. Jeffrey Schouten, AZ Nikolaas
- Dr. Christophe Vansteenkiste, AZ Maria Middelares Gent
BEYOND THE EFFICACY OF HCV TREATMENTS, WHAT DOES REALLY MATTER?
A PROS AND CONS DEBATE

Speakers:

Dr. Nancy Reau
Rush University Medical Center, Chicago, U.S.

Dr. Ashley Brown
Imperial College, London, U.K.

Moderator:

Prof. Anja Geerts
UZ Gent, Belgium

Thursday - February 22, 2018
13.15 – 14.00
10:54 A 12  Short and long-term survival of patients suffering from non-severe alcoholic hepatitis.


11:06 A 13  Angiopoietin-2 as therapeutic target for pathological angiogenesis and inflammation in non-alcoholic steatohepatitis.


11:30  BELIAC Lecture: Surgical management of early HCC.

Chair: Olivier Detry (ULiège)

Resection is the first option:
Valerio Lucidi (ULB Brussels)

Liver transplantation is the first option:
Jacques Pirenne (KULeuven)

12:00  Satellite Symposium Abbvie

Invited Speakers: Prof. I. COLLE, (ASZ Aalst) / Dr. B. BASTENS, (CHC Liège) / Prof. J. (AZ Nikolaas) / Dr C. VANSTEENKISTE, (AZ Maria Middelares Gent)

12:45  LUNCH

13:15  Satellite Symposium MSD

Invited Speakers: Dr. N. REAU, Rush University Medical Center, Chicago (USA) / Dr A. BROWN, Imperial College, London (UK)
The effects of methoxamine and endothelin-1 on the increased transhepatic pressure gradient in a rat model of severe steatosis.


Risk of hepatocellular cancer and fibrosis evolution in HCV patients treated with direct acting antiviral agents.

C. HAMOIR, P. STARKE, G. DAHLQVIST, Y. HORSMANS, N. LANTHIER / UCL Saint-Luc Brussels

The combination of N-acetylcysteine and anti-MT antibodies as novel therapy for acetaminophen-induced liver injury.


The impact of pulmonary arterial hypertension therapy in patients with portopulmonary hypertension: a single tertiary center cohort analysis.


Cytotoxic CD8 T lymphocytes are associated with “active” NASH: from the blood to the liver.

MARC HAUTEKEETE LECTURE: Diagnostic approach of cholestasis: When it is neither PBC nor PSC.

Vincent Leroy (CHU Grenoble, France)
<table>
<thead>
<tr>
<th>ROOMS</th>
<th>3rd FLOOR</th>
<th>LUJN</th>
</tr>
</thead>
<tbody>
<tr>
<td>LUNCH 12h00-14h00</td>
<td>Exhibition Area</td>
<td>Satellite Symposium</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JANSSEN-CILAG 13h15-14h00</td>
</tr>
<tr>
<td>AFTERNOON Coffee Break</td>
<td>Exhibition Area</td>
<td>BIRD Basic</td>
</tr>
<tr>
<td>AFTERNOON</td>
<td></td>
<td>Satellite Symposium</td>
</tr>
<tr>
<td>17h00-17h45</td>
<td></td>
<td>PFIZER 17h00-17h45</td>
</tr>
<tr>
<td>17h45-18h30</td>
<td></td>
<td>General Assembly BIRD</td>
</tr>
<tr>
<td>MORNING</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MORNING Coffee Break</td>
<td>Exhibition Area</td>
<td>Case Reports</td>
</tr>
<tr>
<td>MORNING</td>
<td></td>
<td>Case Reports</td>
</tr>
<tr>
<td>LUNCH 12h00-14h00</td>
<td>Oral Top Basic Posters 12h15-13h</td>
<td>Satellite Symposium TAKEDA 13h15-14h00</td>
</tr>
<tr>
<td>AFTERNOON Coffee Break</td>
<td>Exhibition Area</td>
<td>BIRD Clinical</td>
</tr>
<tr>
<td>AFTERNOON</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16h45-18h30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MORNING</td>
<td></td>
<td>Working Group of Digestive Pathology</td>
</tr>
<tr>
<td>Coffee Break</td>
<td>Exhibition Area</td>
<td>Working Group of Digestive Pathology</td>
</tr>
<tr>
<td>MORNING</td>
<td></td>
<td>Working Group of Digestive Pathology</td>
</tr>
<tr>
<td>LUNCH 12h00-14h00</td>
<td>Oral Top Clinical Posters 12h15-13h</td>
<td>Satellite Symposium BMS Oncology 13h15-14h00</td>
</tr>
<tr>
<td>AFTERNOON Coffee Break</td>
<td>Exhibition Area</td>
<td>Brohée Lecture</td>
</tr>
<tr>
<td>AFTERNOON</td>
<td></td>
<td>Working Group of Digestive Pathology</td>
</tr>
<tr>
<td>18h00-18h45</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## XXXth Edition

### Overview

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Wednesday, 21/02</strong></td>
<td></td>
</tr>
<tr>
<td><strong>LUNCH</strong></td>
<td>12h00-14h00</td>
</tr>
<tr>
<td><strong>Exhibition Area</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Exhibition Area Satellite Symposium</strong></td>
<td></td>
</tr>
<tr>
<td><strong>JANSSEN-CILAG</strong></td>
<td>13h15-14h00</td>
</tr>
<tr>
<td><strong>AFTERNOON</strong></td>
<td></td>
</tr>
<tr>
<td><strong>BIRD Basic</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Belgian Pancreatic Club</strong></td>
<td>Case Reports, Young BASL</td>
</tr>
<tr>
<td><strong>Coffee Break</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Exhibition Area</strong></td>
<td></td>
</tr>
<tr>
<td><strong>AFTERNOON</strong></td>
<td></td>
</tr>
<tr>
<td><strong>BIRD Basic</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Belgian Pancreatic Club</strong></td>
<td>Case Reports, Young BASL</td>
</tr>
<tr>
<td><strong>ULTRA SOUND Course</strong></td>
<td>17h00-19h00</td>
</tr>
<tr>
<td><strong>Thursday, 22/02</strong></td>
<td></td>
</tr>
<tr>
<td><strong>MORNING</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Breakfast Symposium INTERCEPT</strong></td>
<td>8h00-8h30</td>
</tr>
<tr>
<td><strong>BASL</strong></td>
<td>GIREM</td>
</tr>
<tr>
<td><strong>BASL</strong></td>
<td>GIREM</td>
</tr>
<tr>
<td><strong>Satellite Symposium ABBVIE</strong></td>
<td>12h00-12h45</td>
</tr>
<tr>
<td><strong>BASL</strong></td>
<td>GIREM</td>
</tr>
<tr>
<td><strong>Satellite Symposium MSD</strong></td>
<td>13h15-14h00</td>
</tr>
<tr>
<td><strong>BASL</strong></td>
<td>BSGIE</td>
</tr>
<tr>
<td><strong>Satellite Symposium GILEAD</strong></td>
<td>16h45-17h30</td>
</tr>
<tr>
<td><strong>Satellite Symposium PFIZER/BMS</strong></td>
<td>16h45-17h30</td>
</tr>
<tr>
<td><strong>Acta GA</strong></td>
<td>17h30-18h30</td>
</tr>
<tr>
<td><strong>Friday, 23/02</strong></td>
<td></td>
</tr>
<tr>
<td><strong>MORNING</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Breakfast Symposium ELI LILLY</strong></td>
<td>8h00-8h30</td>
</tr>
<tr>
<td><strong>BGDO</strong></td>
<td>Proctology</td>
</tr>
<tr>
<td><strong>BGDO</strong></td>
<td>Proctology</td>
</tr>
<tr>
<td><strong>Satellite Symposium SERVIER</strong></td>
<td>12h00-12h45</td>
</tr>
<tr>
<td><strong>GBS-VBS</strong></td>
<td>General Assembly</td>
</tr>
<tr>
<td><strong>LUNCH</strong></td>
<td>12h00-14h00</td>
</tr>
<tr>
<td><strong>Exhibition Area</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Award Ceremony</strong></td>
<td>13h00-13h15</td>
</tr>
<tr>
<td><strong>Satellite Symposium BMS Oncology</strong></td>
<td>13h15-14h00</td>
</tr>
<tr>
<td><strong>Brohée Lecture</strong></td>
<td>16h45-18h45</td>
</tr>
<tr>
<td><strong>Working Group of Digestive Pathology</strong></td>
<td>BGDO Proctology, GIREM</td>
</tr>
<tr>
<td><strong>Live Transmission Session BeSPGHAN</strong></td>
<td>17h00-18h30</td>
</tr>
<tr>
<td><strong>Live Transmission Session</strong></td>
<td>18h00-18h45</td>
</tr>
<tr>
<td><strong>Overview</strong></td>
<td>XXXth Edition</td>
</tr>
</tbody>
</table>
IS NASH THE NEXT HCV?

What can we learn from our Hepatitis C experience to better manage our NASH patients?

SPEAKER

Professor Philippe Mathurin
Head of the Department of Hepato-Gastroenterology
Centre Hospitalier Régional Universitaire de Lille, France

MODERATOR

Professor Sven Francque
Head of the Department of Hepato-Gastroenterology
University Hospital Antwerp, Belgium

THURSDAY 22ND FEBRUARY
From 16:45 to 17:30
Hilton Antwerp, Room Teun
16:00  A 20  Insulin resistance in cirrhotic patients: results from a large prospective study.

16:10  A 21  Fibroscan is a useful and reliable tool to rule out advanced liver fibrosis and severe portal hypertension in alcoholic patients.
M. SALAVRAKOS, N. LANTHIER, P. STARKEL / UCL Saint-Luc Brussels

16:20  A 22  The effects of NO modulators on the increased transhepatic pressure gradient in a rat model of severe steatosis.

16:30  A 23  Estimation of the future liver remnant function is a better tool to predict post-hepatectomy liver failure than platelet-based liver scores.

16:40  BASL Awards for best Basic and Clinical work presented.

16:45  Satellite Symposium GILEAD
Invited Speaker: Prof. P. MATHURIN

17:30  BASL General Assembly
A24  Morphological features of spontaneous bacterial peritonitis in cirrhotic patients.
D. HAURYLENKA, T. HAURYLENKA / Republican Research Center for Radiation Medicine and Human Ecology, Gomel, Belarus

A25  Screening for hepatitis C viral infection in a non-urban primary care facility in Flanders.

A26  Liver transplantation for alcoholic hepatitis: a systematic review with meta-analysis.

A27  Effects of GLP-1 receptor polymorphisms on adolescent obesity.
M. MARALANI / UZ Antwerpen

A28  Under constant injury ductular-derived hepatocytes clonally grow as robust carcinoma genesis-resistant population

A29  Point-of-care diagnostic tests for HBV and HCV are associated with a higher linkage to care in an Asian migrant population.

A30  Liver transplantation in Jehovah’s witnesses.
M. VANDERMEULEN, N. MEURISSE, P. DAMAS, A. KABA, A. LAMPROYE, J. DELWAIDE, J. JORIS, P. HONORÉ, O. DETRY / CHU Liège

A31  Alveolar echinococcosis is now endemic in southern Belgium.

A32  Descriptive epidemiologic data on liver cancer in Belgium, 2004-2025.

A33  Multivisceral transplantation for diffuse portomesenteric thrombosis: a case series.
A34   Cu isotope ratio shifts in common bile duct ligated mice and correlates with the degree of cholestatic-induced liver disease.

A35   CD4+ RORγt+ T cells, CD4+ T-bet+, CD4+ CD25+ Foxp3+ T cells and CD8+ T cells are differentially altered in liver and adipose tissue of mice fed a high-fat high-fructose diet in a time-dependent manner.

A36   Who to screen for hepatitis C in Belgium? Cost-effectiveness study of comprehensive hepatitis C screening in four target groups.

A37   Retrospective analysis of HCV infected individuals in a Belgian Regional Hospital.
L. BRUWIER, G. BASTENS, N. CIELNIASZEK, D. GRAAS, B. BASTENS / CHC Clinique Saint-Joseph, Liège

A38   The impact of intra-patient variability in tacrolimus pre-dose concentrations on patient outcomes in pediatric liver transplantation recipients.

A39   Loss-to-follow-up is an important problem in the diagnosis and follow-up of hepatitis C.

A40   The association between chronic hepatitis C infection and colon cancer: a nationwide case-control study.
N. LE / Taipei Medical University, Taiwan (Province of China)

A41   Estimation of the future liver remnant function supports parenchyma-saving hepatectomy combined with hepatic vein resection and reconstruction.
T. CHAPELLE, B. OP DE BEECK, G. ROEYEN, V. HARTMAN, B. BRACKE, D. YSEBAERT / UZ Antwerpen

A42   Estimation of the future liver remnant function prior to hepatectomy may guide the indication for portal vein occlusion and avoid post-hepatectomy liver failure: a prospective interventional study.
SESSION 1
CHAIRS: B. De Winter (UAntwerpen), G. Boeckxstaens (KULeuven)

9:00 B 01 Predictors for colonic manometry outcome related to high-amplitude propagating sequences.

9:15 B 02 Fecal microbiota transplantation in irritable bowel syndrome with predominant abdominal bloating: results from a double blind, placebo-controlled, randomized controlled trial.

9:30 B 03 Effects of Nafamostat Mesylate on intestinal permeability and bacterial translocation in an experimental model of sepsis.

9:45 B 16 Invited Lecture: The touchy business of GI mucosal mechanosensitivity.
A. BEYDER / Rochester, USA

10:30 Coffee Break

SESSION 2
CHAIRS: J.-P. Timmermans (UAntwerpen), P. Vanden Berghe (KULeuven)

11:00 Invited Lecture: Enteric neurons and mechanosensitivity: MEN at work.
G. MAZZUOLI-WEBER / Hannover, Germany

11:45 B 04 Mrgprc11 is expressed in murine viscerosensory spinal neurons: an immunohistochemical and retrograde tracing study.
S. VAN REMOORTEL, J. DE MAN, B. DE WINTER, R. BUCKINX, J.-P. Timmermans / UAntwerpen

12:00 B 05 Live calcium imaging reveals neuronal circuitry differences in the mouse colon.
Inadequately treated primary biliary cholangitis (PBC) can lead to liver transplantation or death$^{1,2}$

Up to 40% of patients taking ursodeoxycholic acid (UDCA), may not be achieving an adequate response to treatment, as indicated by a GLOBE score of >0,30. So it is important to monitor your patients regularly$^3$.

Alkaline phosphatase (ALP), bilirubin, age, albumin and platelet count are markers of both disease progression and response to therapy.$^3$ A GLOBE score of >0,30 in PBC patients is associated with significantly shorter times of transplant-free survival than matched healthy individuals (P < 0,0001).$^3$

EASL recommends checking your patients’ response to therapy one year after starting therapy.

Check your patient’s GLOBE score at www.globalpbc.com/globe
12:15  B 06  Upregulation of mast cell related genes in irritable bowel syndrome.

12:30  Lunch

SESSION 3
CHAIRS: R. Lefebvre (UGent), W. Boesmans (KULeuven)

13:30  Invited Lecture: Lipids and irritable bowel syndrome – an (un)likely connection.
J. FICHNA / University of Lodz, Poland

14:15  B 07  Food antigen-specific sensitization of nociceptive nerves as an underlying mechanism of visceral pain in IBS.

14:30  B 08  Double-blind randomized placebo-controlled trial of a probiotic combination ProbiTer in irritable bowel syndrome.

14:45  B 09  Prospective study evaluating predisposing factors and immune-mediated mechanisms underlying post-infectious IBS.

15:00  B 10  Long term adherence and effects of low FODMAP diet in patients with IBS.

15:30  Coffee Break
16:15  B 12  The circadian clock regulates diurnal rhythmicity of microbial short-chain fatty acid production and their rhythmic effects on colon contractility.
SEGERS, L. DESMET, T. THYS, K. VERBEKE, J. TACK, I. DEPOORTERE / KULeuven

J. VAN DINGENEN, R. LEFEBVRE / UGent

16:45  B 14  Effect of resolvin D1, D2 and E1 on histamine-induced sensitization of TRPV1.
E. PERNA, M. FLORENS, J. AGUILERA, S. THEOFANOUS, L. DECRAECKER, M. WOUTERS, G. BOECKXSTAENS / KULeuven

17:00  B 15  In toto three-dimensional microscopical imaging of the intestinal wall: comparison of eight clearing protocols.

17:15  Concluding remarks
I. DEPOORTERE / KULeuven
SESSION 2: Interactive Case Report

CHAIRS: P. Caenepeel (ZOL, Genk), C. Van Kemseke (CHU Liège)

09:00   C 09  Endoscopic submucosal dissection of a granular tumour of the oesophagus: a Case Report.
C. DE VLOO (1), F. MAROLLEAU (2), J. DEWYSPELAERE (2), L. DESOMER (2), E. STEENKISTE (2), D. DE WULF (2)

09:20   C 10  Two rare conditions at the same time after gastric bypass in a young female.
D. DOOREMONT / AZ Sint-Elisabeth, Zottegem

09:40   C 11  A case of severe enteropathy.
P. HENRY, H. DANO, H. PIESSEVAUX, A. JOURET-MOURIN / UCL Saint-Luc

10:00  Coffee Break

CHAIRS: P. Caenepeel (ZOL, Genk), C. Van Kemseke (CHU Liège)

10:20   C 12  Probiotics in a critically ill malnourished patient: to do or not to do.
M. FIGUEIREDO, T. SERSTÉ, M. VAN GOSSUM / CHU Saint-Pierre

10:40   C 13  An unusual cause of gastrojejunal anastomotic stenosis after Roux-en-gastric bypass.

11:00   C 14  Adenocarcinoma of the gastroesophageal junction after bariatric surgery: Two cases reports.
M. VAN GOSSUM, M. FIGUEIREDO, E. BRAUNS, P. EISENDRATH / CHU Saint-Pierre

M. STRUYVE, H. VAN VEER, L. DEPYPERE, P. NAFTEUX, P. ROELANDT/ UZ Leuven

11:40   C 16  Unusual yellow to orange colonic mucosal appearance: what could that be?

11:50  Q & A

12:00  End of the Session
CD4+ RORγt+ T cells, CD4+ T-bet+, CD4+ CD25+ Foxp3+ T cells and CD8+ T cells are differentially altered in liver and adipose tissue of mice fed a high-fat high-fructose diet in a time-dependent manner.


Epidemiology of Clostridium difficile infections in IBD over two decades.


Under constant injury ductular-derived hepatocytes clonally grow as robust carcinogenesis-resistant population.


Cu isotope ratio shifts in common bile duct ligated mice and correlates with the degree of cholestatic-induced liver disease.


The interaction between intestinal permeability disturbances and inflammation in a chronic colitis mouse model, studied over time.

H. VAN SPAENDONK, J. DE MAN, S. FRANCQUE, H. DE SCHEPPER, B. DE WINTER / UZ Antwerpen

Identification of new pathways driving muscle atrophy and biomarkers reflecting muscle atrophy in cancer cachexia.


Potential diagnostic biomarkers of Ulcerative colitis-associated colorectal dysplasia.


Serum proteomic profiling in Crohn’s disease patients undergoing ileocolonic resection reveals discriminative inflammatory markers for endoscopic recurrence.


Q & A
SESSION 3: JAK inhibition
CHAIRS: Pieter Dewint (Gent), Jean-François Rahier (Namur)

13:15 Satellite Symposium Takeda
Invited speaker: Shomron Ben-Horin, Tel-Aviv, Israel

14:00 Invited Lecture: JAK inhibitors: can they replace biologicals?
Charlie Lees / Edinburgh, UK

14:25 I09 Thiopurine monotherapy still has a place in the treatment of patients with mild-to-moderate Crohn’s disease in the biological era.
L. BOETS, B. VERSTOCKT, G. VAN ASSCHE, S. VERMEIRE, M. FERRANTE / UZ Leuven

14:35 I10 Ustekinumab induces clinical and biological remission in biologic refractory Crohn’s disease patients.

14:45 I11 Risk of cmv reactivation in uc patients with previous history of cmv infection following infliximab or vedolizumab treatments.
C. HOMMEL (1), X. ROBLIN (2), L. BRICHET (2), B. BIHIN (1), S. PILLET (2), J. RAHIER (1) / [1] CHU UCL Namur, Yvoir, [2] University Hospital Saint Etienne, France

14:55 I12 Ustekinumab induces limited mucosal healing after 6 months in a real-life, prospective cohort of patients with refractory Crohn’s disease.

15:05 Invited Lecture: JAK inhibitors: is the increased risk of viral infections a real threat?
Marc Van Ranst / Leuven

15:30 Coffee Break
Takeda Satellite Symposium

February 22nd from 13h15 till 14h00

PK/PD for guiding therapy with vedolizumab: lessons from clinical experience

Prof. Dr. Shomron Ben-Horin

Associate Professor and Director of the inflammatory bowel disease (IBD) service at Sheba Medical Center, Tel-Aviv University, Israel.
16:00 I13 Effectiveness and persistence of vedolizumab in patients with inflammatory bowel disease: Results from the Belgian REal-Life study with VEdolizumab (Be-RELIVE).

16:10 I14 Vedolizumab trough levels during induction in ibd patients: a longitudinal observational retrospective study.

16:20 I15 Vedolizumab can induce clinical remission in patients with chronic antibiotic refractory pouchitis: a retrospective single centre experience.
C. CLAEYS, B. VERSTOCKT, G. VAN ASSCHE, A. D‘HOORE, A. WOLTHUIS, S. VERMEIRE, M. FERRANTE / UZ Leuven

16:30 I16 Outcome of pregnancies in vedolizumab treated female IBD patients.

16:40 Invited Lecture: Initiating biological therapies in IBD: do I have to use other drugs for CD than for UC?
Shomron Ben-Horin / Tel Aviv, Israel
Thursday 22

E - POSTERS

13:00 SESSION 1: Guided e-Poster Tour

CHAIRS: T. Moreels (UCL Saint-Luc, Brussels),
A. Lemmers (ULB Erasme, Brussels),
X. Dekoninck (Clinique St-Pierre Ottignies), D. Blero (CHU Charleroi)

G 09 Intraductal cholangioscopy and pancreatoscopy indications and results.
A. TAHA, R. GARCES DURAN, T. MOREELS, R. YEUNG, T. AOUATTAH, M. KOMUTA, H. PIESSEVAUX, P. DEPREZ / UCL Saint-Luc Brussels

G 10 Transanal endolaparoscopy: an innovative treatment of Colorectal anastomotic leakages.
G. DAPRI, V. MULS, R. NTOUNDA, M. VAN GOSSUM, M. BUSET, P. EISENDRATH / CHU Saint-Pierre, Brussels

G 11 @ERCP in patients with Roux-en-Y altered anatomy and intact Vater’s papilla.
E. AKPOKAVIE, A. SLIMANI, P. DEPREZ, H. PIESSEVAUX, T. MOREELS / UCL Saint-Luc, Brussels

G 12 Endoscopic treatment of postoperative fistulas in the upper gastrointestinal tract.
T. ROOSVELT, B. NAVEZ, M. THOMA, Y. DESWYSEN, P. DEPREZ, H. PIESSEVAUX, T. MOREELS / UCL Saint-Luc, Brussels

G 13 Is Lugol necessary for endoscopic resection of squamous cell neoplasia of the esophagus?

G. BURNET, Y. HOEBEKE, F. CORBISIER, P. WARZÉE / GHDC, Charleroi

G 15 Endoscopic management of biliary leaks: a systematic review.
K. VLAEMYNCK, P. HINDRYCKX / UZ Gent

G 16 EUS-guided biliary drainage and EUS-guided rendezvous technique when ERCP fails. A single center cohort database.
D. DE WULF, L. DESOMER, F. BAERT / AZ Delta, Roeselare

G 17 Persistent pain after colonic endoscopic mucosal resection: Predictors, a management algorithm and outcomes.

G 18 Intraductal ablation by radiofrequency probe or cystostome during Endoscopic ampulllectomy may reduce the long-term recurrence rate.
E. PEREZ-CUADRADO, H. PIESSEVAUX, T. MOREELS, A. JOURET-MOURIN, P. DEPREZ / UCL Saint-Luc, Brussels
14:00 G01 Automated digital calculation of endoscopic inflammation in ulcerative colitis: results of the red density study.


14:15 G 02 Endobiliary radiofrequency ablation in patients with inoperable biliopancreatic tumors complicated with obstructive jaundice: the IGNITE-1 trial.


14:30 G 03 Simple endoscopic treatment of adenoma recurrence after wide field endoscopic mucosal resection is effective: A prospective study of 1558 lesions with long term follow up.


14:45 G 04 Self-sizing radiofrequency ablation balloon for eradication of Barrett’s esophagus: results of an international multicenter randomized trial comparing three different treatment regimens.


15:00 Invited Lecture: ESGE quality indicators for lower GI endoscopy.

Marek Bugajski / Warsaw, Poland

15:30 Coffee break.
Anticoagulation & GE: Where are we after 5 years of NOAC?
Interactive dialogue between 2 specialists and the audience

Satellite Symposium
Thursday February 22, 2018
Timing: 17:20 - 18:05

Moderator
Prof. Daniel Blero, CHU Charleroi
President of BSGIE

Speakers
Prof. Pierre Deprez, UCL - Gastroenterology
Prof. Kristin Jochmans, UZ Brussels - Hematology

SPC and full Prescribing Information will be available at BMS Pfizer Alliance Exhibition Booth
GE: Gastroenterology
NOACs: non-vitamin K antagonist oral anticoagulants

This Satellite Symposium is fully organised and funded by:
Bristol-Myers Squibb Pfizer

Date of preparation: December 2017 - 432BE17PR09571-171252
16:00 G 05 An international survey of colorectal polypectomy practice demonstrates encouraging adherence to published guidance.

16:12 G 06 Higher mean boston bowel preparation scale scores with 1l pegbased ner1006 versus 2l peg + ascorbate: post hoc analysis of a randomised phase 3 clinical trial.

16:24 G 07 Launching an Endoscopic Submucosal Dissection (ESD) program in a European academic hospital: review of the first 28 months of experience.

16:36 G 08 EUS today and tomorrow: what are we doing today in real practice in different countries and where are we going?: a Belgian survey.

16.50 Invited Lecture: Optical diagnosis: how do I do it?
E. Dekker / Amsterdam, Netherlands

17:20 Satellite Symposium BMS/PFIZER Alliance
This year, the Belgian week organizes once again a practical, hands on session in ultrasound on Wednesday and Thursday afternoon.

Thursday afternoon the session will focus on ultrasound in bowel pathology. For this course, we aim to gastroenterologists with interest in bowel disorders and the role of abdominal ultrasound.

After a short introduction, participants will be instructed on simulators from the Hannover University. The machines that will be used for the course are simulators demonstrating real life images of abdominal pathology. During the session we will focus on inflammatory bowel disorders.
Thursday February 22nd
BWGE XXXth Anniversary

VENUE
The top floor of the MAS Museum
Hanzestedenplaats, 5 – 2000 Antwerpen

Time:
7:30 pm XXXth Anniversary Celebration & Aperitive
8:30 pm Dinner & Party

Bus transfers:
7:00 pm Departure from the Hilton Hotel
11:00 pm – 12:00 pm – 1:00 am
Departures from the MAS Museum

Registration: 35€ for registered participants 80€ for an accompanying person.
A lot of memories from all these years, make sure to reserve your place!
Lower gastro-intestinal endoscopy: Are we doing well? How can we do better?

Live endoscopy from ULB Erasme, Brussels with demonstration and discussion about implementation of key indicators of performance in colonoscopy. Different aspects of colonoscopy will be considered:

- Application of diagnosis techniques,
- Evaluation and treatment of common clinical situations (screening colonoscopy,
- IBD evaluation and description, polyps assessment and description, polypectomy techniques, tattooing policy…), adequate reporting,
- Evaluation of complication rate,
**BWGE 2018 Grants:**

**BWGE 2018 Research Grant**  
Laurens Ceulemans, KUL  
Villin-1 is a novel serological biomarker for intestinal ischemia and reperfusion injury in rats and humans  
Promotor Pr. J. Pirenne  
Abdominal Transplantation Surgery, University Hospitals Leuven, Belgium; Microbiology and Immunology, KULeuven, Belgium  

**BWGE 2018 Research Grant**  
Tanguy Demaret, UCL  
Study of extracellular vesicles released by liver and umbilical cord mesenchymal stem cells to restore peroxisome biogenesis in Zellweger spectrum disorders  
Promotor Pr E. Sokal  
Lab Paediatric hepatology and cell therapy lab (PEDI)  
Université Catholique de Louvain  
Brussels  

**BWGE 2018 Research Grant**  
Astrid Vandierendock, UGhent  
Characterisation of the UPR and DUB (deubiquitinases) signature in the CSCs (cancer stem cells) of human primary HCCs  
UGhent (H. Van Vlierberghe) & KUL (T. Roskams)  
DUB (deubiquitinases)  
CSCs (cancer stem cells)  

**ACTA Gastroenterologica Grant**  
Lisbeth Vandenabeele  
The predictive value of negative capsule endoscopy for the indication of Obscure Gastrointestinal Bleeding: no reassurance in the long term.  
Cedric Van de Bruaene, Pieter Hindryckx, Christophe S nauwaert, Diederik Dooremont, Bruno Vanduyfhuys, Martine De Vos, Danny De Looze.

**BWGE 2018 Prizes:**  
Best Clinical Poster  
Best Basic Poster  
BIRD Prize  
BeSPGHAN Prize  
BGDO Prize
### SESSION 1: Infectious anorectal diseases and selected abstracts

**CHAIRS:** C. Van Kemseke (U Liège), H. De Schepper (UZ Antwerpen)

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:15</td>
<td>M 02</td>
<td>Injection of botulinum toxin in the treatment of anal fissure can be performed safely in patients actively receiving chemotherapy.</td>
<td>P. ROELANDT (1), G. COREMANS (1), J. WYNDAELE (1) / [1] UZ Leuven, Gastroenterology and Hepatology</td>
</tr>
<tr>
<td>9:30</td>
<td></td>
<td>Invited Lecture: Sexually transmitted diseases of the anorectum.</td>
<td>D. DE LOOZE / UZ Gent, Gastroenterology and coloproctology</td>
</tr>
<tr>
<td>10:00</td>
<td>M 03</td>
<td>Hemorrhoidal disease in Belgian clinical practice: Results of the CHORUS study (Chronic venous and HemORrhoidal diseases evalUation and Scientific research).</td>
<td>H. DE SCHEPPER (1), M. SOMERS (1), D. DE LOOZE (2) / [1] UZ Antwerpen, Gastroenterology &amp; Hepatology, [2] UZ Gent, Gastroenterology</td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td>Coffee break</td>
<td></td>
</tr>
</tbody>
</table>

### SESSION 2

**CHAIRS:** P. Roelandt (UZ Leuven), MA Denis (UCL Brussels)

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:10</td>
<td></td>
<td>Invited Lecture: Manifestations of Human Papilloma Virus infection at the anal canal – anal intraepithelial neoplasia – early detection and prevention.</td>
<td>O. RICHEL / Dep. of Infectious Diseases, Academic Medical Center, Amsterdam</td>
</tr>
<tr>
<td>11:40</td>
<td></td>
<td>What you’ve always wanted to know but never dared to ask: tips and tricks for frequent and unusual proctology cases (interactive session)</td>
<td>MA DENIS / UCL Brussels and P ROELANDT / UZ Leuven</td>
</tr>
</tbody>
</table>
8:00 Breakfast Satellite Symposium LILLY

Speakers: Prof. M. Van den Eynde, Prof. Van Buistem, Prof S.L Van Laethem, Prof. M Peeters

SESSION 1
CHAIRS: Alain Hendlisz (ULB Bordet, Brussels), Karen Geboes (UZ Gent)

8:30 O 01 Prognostic value of tumor location in colorectal carcinoma: a Belgian population based study.

8:42 O 06 A novel post-surgical prognostic system for colorectal liver metastases treated by preoperative systemic treatment, using tumoral and non tumoral pathological changes, RAS mutation and Immunoscore.

8:54 O 03 Preoperative gemcitabine-nab-paclitaxel (G-NP) for (borderline) resectable (BLR) or locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC): a feasibility and proof of concept study.

Y. MANDEVILLE, J. MOONS, A. RINGOET, L. DEPYPERE, W. COOSEMANS, H. VAN VEER, P. NAFTEUX / UZ Leuven

9:18 O 05 Long term oncological results and quality of life after HIPEC for carcinomatosis of colorectal origin.
BGDO Session and Satellite Symposia during the Belgian Week of Gastroenterology

Friday 23 February 2018 - Hilton Antwerp - Meeting room TEUN

In collaboration with BGDO, Lilly organises a breakfast meeting during the Belgian week of Gastroenterology.

Optimizing sequential treatment in gastric cancer

Patient case and discussion

Case presenter: Prof. Marc Van den Eynde
Panel experts: Prof. Eric Van Cutsem | Prof. Jean-Luc Van Laethem | Prof. Marc Peeters

Leave on time to avoid the traffic jam and enjoy breakfast as from 7:45!

Looking forward to meeting you all on 23 February at the Hilton hotel.
Redefining third line therapy in metastatic colorectal cancer

will be discussed using patient cases in an interactive way during 45 minutes.

Case presenters: Prof. Marc Peeters | Prof. Marc Van den Eynde
Chairmen: Prof. Eric Van Cutsem | Prof. Jean-Luc Van Laethem

Looking forward to meeting you all on 23 February at 12 o’clock
for a lunch meeting at the Hilton hotel.
9:30  O 02  Clinical Application and Potential Usefulness of Targeted Next-Generation Sequencing on Resected Pancreatic Ductal Adenocarcinoma.

9:42  O 07  Inter-center heterogeneity in the quality of care for rectal adenocarcinoma in Belgium.

9:54  Coffee break

SESSION 2:  Highlights of the year
CHAIRS:  Ivan Borbath (UCL Saint-Luc, Brussels), Marc Peeters (UZAntwerpen)

10:30  Upper GI cancers.
Marc Van Den Eynde / UCL Saint-Luc, Brussels

10:50  Hepato-Bilio-Pancreatic cancers.
Anne Demols / ULB Erasme Brussels

11:10  Colo-Rectal cancers.
Hans Prenen / UZ Leuven

11:30  Invited Lecture: “MSI testing in GI cancer: challenges and pitfalls”
Magali Svrcek / Hôpital Saint-Antoine, Paris, France

12:00  Satellite Symposium SERVIER.
Invited Speakers: Prof. M. VAN DEN EYNDE / Prof. E. VAN CUTSEM / Prof J-L. VAN LAETHEM
Prof. M. PEETERS

12:45  Lunch
**E - POSTERS**

**O08** Identification of new pathways driving muscle atrophy and biomarkers reflecting muscle atrophy in cancer cachexia.


**O09** A Centre-based Study of Clinical and Molecular Characteristics of Post-Colonoscopy Colorectal Cancer.


**O10** Estimation of the future liver remnant function is a better tool to predict post-hepatectomy liver failure than platelet-based liver scores.


**O11** Estimation of the future liver remnant function supports parenchyma-saving hepatectomy combined with hepatic vein resection and reconstruction.

T. CHAPELLE, B. OP DE BEECK, G. ROEYEN, V. HARTMAN, B. BRACKE, D. YSEBAERT / UZAntwerpen

**O12** Estimation of the future liver remnant function prior to hepatectomy may guide the indication for portal vein occlusion and avoid post-hepatectomy liver failure: a prospective interventional study.


**O13** Next-generation sequencing in cholangiocarcinoma: the quest for applicability and precision therapy!

Are we understanding immunotherapy?
Challenges & Opportunities

› **Friday 23rd of February:**
  Satellite Symposium B-MS

› **Programme**

  13.15 - 13.35  Understanding Immunoscience: basics of Immunology
                 › *Prof. Pierre Coulie, UCL Brussels*

  13.35 - 14.00  Future Trends in Immunotherapy
                 › *Prof. Eric Van Cutsem, UZ Leuven*
SESSION 1
CHAIRS: A. Hoorens (UZ Gent), P. Baldin (UCL Saint-Luc, Brussels)

9:00  Introduction.
A. Hoorens (UZ Gent)

9:05  Invited Lecture: Non-HP gastritis.
M. Rugge / Padova, Italy

9:40  R 01  An unusual gastric polyp.
C. Van Paesschen, E. Macken, P. Pauwels, A. Snoeckx, M. Ruppert, A. Driessen / UZ Antwerpen

9:50  R 02  Granular cytoplasmic expression of calretinin in Schwann cell hamartomas.

10:00  Coffee Break

G. Cathomas / Liestal, Switzerland

11:20  R 03  Myxoid hepatocellular adenoma, a rare variant of liver cell adenoma, often clinically misdiagnosed as cavernous haemangioma.
A. Hoorens, A. Candaele, M. Van der Linden, P. Smeets, C. Lecluyse, N. De Vos, R. Troisi, J. Van Dorpe / UZ Gent

A. Driessen / UZ Antwerpen

12:00  Lunch

14:00  Introduction to the Brohée Prize.
Ivan Borbath (UCL Saint-Luc Brussels)

14:05  Brohée Prize Lecture: “Personalized medicine in GI oncology: myth or reality”.
S. Tejpar (KULeuven)
SESSION 2
CHAIRS: A. Driessen (UZ Antwerpen), L. Verset (ULB Erasme Brussels)

14:30  Invited Lecture: Neuroendocrine neoplasms of the GI tract: NET, NEC and MiNEN in the WHO 2017 classification.
A. Hoorens / UZ Gent

15:00  R 04  Frequency of epidermal metaplasia in a retrospective monocentric series of mucosectomy for esophageal intraepithelial neoplasia and/or superficial squamous cell carcinoma.

15:10  R 05  Endothelial indoleamine 2,3-dioxygenase expression in colorectal cancer: an early marker of disease relapse.

15:20  Coffee Break

15:45  Case presentations of “Non-HP gastritis” and “Non-IBD colitis”.
- S. Bigoundou-Nzamba (ULB Erasme Brussels)
- G. Broeckx (UZ Antwerpen)
- A. Candaele (UZ Gent)
- A. De Roo (UZ Leuven)
- P. Henry (UCL Saint-Luc, Brussels)
- H. Van Beveren (UZ Gent)

16:45  Invited Lecture: Disorders of the colon secondary to diagnostic procedures and treatments unrelated to drugs.
L. Libbrecht / UCL Saint-Luc, Brussels
13:30  Diagnostic value of faecal calprotectine.
Els Van de Vijver / UZAntwerpen

Karen Van Hoeve / UZ Leuven

14:10  Human milk oligosaccharides in clinical studies.
Philippe Alliet / Jessa Ziekenhuis, Hasselt

14:30  Gastric emptying in children in health and disease: an update for daily clinical practice.
Bruno Hauser / UZ Brussel

14:50  Coffee break

15:20  K 01  Infliximab trough levels after induction therapy are predictive for the outcome in paediatric patients with inflammatory bowel disease.

15:30  K 02  Infliximab trough levels during maintenance are predictive for infliximab efficacy in paediatric patients with inflammatory bowel disease.
15:40  K 03  Medical devices in EU claiming oropharyngeal or gastrointestinal barrier action: barrier products or hidden pharmacological agents?

15:50  Diagnostic and therapeutic challenges in pediatric chronic pancreatitis.
Isabelle Scheers / UCL St Luc, Brussels

16:20  Immunological consequences of liver transplantation in children: making or breaking tolerance.
Ruth De Bruyne / UZ Gent

16:40  General Assembly BeSPGHAN.

E - POSTERS

K04  Natural history of diarrhoea among under-five children in nalchity, Bangladesh.
M. KHANAM / Centre for Injury Prevention and Research, Dhaka, Bangladesh

K05  Medical devices marketed as medicines: safety and regulatory concerns in children.

N01  Shifting paradigms in Intestinal Transplantation: from rescue therapy to standard of care for intestinal failure?
E-Posters with short oral presentation: Clinical
E-Posters Area in the Exhibition

CHAIRS: I. Colle (Aalst & UZGent), G. Verset (ULB Erasme).

12:15 A 26 Liver transplantation for alcoholic hepatitis: a systematic review with meta-analysis.

12:20 A 31 Alveolar echinococcosis is now endemic in southern Belgium.

12:25 A 39 Loss-to-follow-up is an important problem in the diagnosis and follow-up of hepatitis C.

12:30 Estimation of the future liver remnant function is a better tool to predict post-hepatectomy liver failure than platelet-based liver scores.

12:40 G 09  **Intraductal cholangioscopy and pancreatoscopy indications and results.**


12:45 I 36  **The clinical utility of a multi-marker serum test for assessment of ulcerations in infliximab treated patients with Crohn’s disease.**


12:50 I 35  **Beclomethasone dipropionaat is effective for microscopic colitis: results of an open label multicenter study (COLCO).**


12:55 Q & A
Belgian Week of Gastroenterology
asbl / vzw

SAVE THE DATE 20 > 22.02.2019

www.bwge.be
**SESSION 1**

**CHAIRS:** An Sterckx, Valérie Wambacq, Marleen Goossens

**09:00** Welcome and introduction
Liesbeth Moortgat, AZ Delta Roeselare

**09:15** Patient empowerment: The key to treatment success in IBD
Prof. Pieter Hindryckx, UZ Gent

**09:45** Colon cancer in IBD: Natural history and recommendations for screening and surveillance
Prof. Denis Franchimont, ULB Erasme Brussels

**10:15** Therapeutic treatment with ustekinumab
Dr. Harald Peeters and Sophie Claeyts, AZ St Lucas Gent

**10:45** Coffee Break sponsored by AbbVie

**SESSION 2**

**CHAIRS:** Patricia Geens, Frederika Van Dyck, Liesbeth Moortgat

**11:15** Primary sclerosing cholangitis
Dr. Sofie Decock, AZ St Lucas Brugge

**11:45** Dermatologic manifestations in IBD
Prof. Siegfried Segaert, UZ Leuven

**12:15** Clinical studies for dummies
Ils Van de Schoot, Imelda hospital Bonheiden & Sofie Himpe, AZ Groeninge Kortrijk

**12:45** Closing Session
Valérie Wambacq, ULB Erasme Brussels

**13:00** Lunch sponsored by Takeda

**14:00 - 17:00** BSGIE Live transmission

www.bwge.be
With the Kind Support of our Partners, BWGE becomes possible!

Thank you!

PLATINUM

*Gilead*

*MSD*

*Takeda*

GOLD

*AbbVie*

*BMS - Pfizer Alliance*

*Bristol-Myers Squibb Belgium*

*SANSSSEN-CILAG*

*Pfizer*

*Servier*

SILVER

*Boston Scientific*

*Celgene*

*Intercept*

*Lilly*

*mundipharma*

*Norgine*

*Olympus*

*Pentax Medical*

BRONZE

Acta Gastroenterologica

Analogic Benelux

Benetec

Biocodex

Boucart Medical

BTG Biocompatibles

Cook Medical

Dr Falk Pharma

Echosens

Erbe

Laborie

Lamepro

Mead Johnson

Mediquality

MPS - Vivactis

Mylan

Nestlé

Phacobel

Roche Software

RVC

Sandoz

Selinion

Shire

Tilman

Tramedico

What’s up doc?

Will Pharma

ASSOCIATIONS

F.A.P.A

CHAC

CHROHN FR

CHROHN NL

GBS - VBS

NASH EDUCATION PROGRAM

www.bwge.be